Research ExplorerPublicationsLack of evidence for predictive and prognostic value of cycl...

Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma

Standard

Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma. / Atac, Artun; Riecke, Björn; Assaf, Alexandre T; Gröbe, Alexander; Friedrich, Reinhard E; Heiland, Max; Izbicki, Jakob R; Kluwe, Lan; Blessmann, Marco.

In: ANTICANCER RES, Vol. 34, No. 1, 01.01.2014, p. 235-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Atac, A, Riecke, B, Assaf, AT, Gröbe, A, Friedrich, RE, Heiland, M, Izbicki, JR, Kluwe, L & Blessmann, M 2014, 'Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma', ANTICANCER RES, vol. 34, no. 1, pp. 235-8.

APA

Atac, A., Riecke, B., Assaf, A. T., Gröbe, A., Friedrich, R. E., Heiland, M., Izbicki, J. R., Kluwe, L., & Blessmann, M. (2014). Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma. ANTICANCER RES, 34(1), 235-8.

Vancouver

Atac A, Riecke B, Assaf AT, Gröbe A, Friedrich RE, Heiland M et al. Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma. ANTICANCER RES. 2014 Jan 1;34(1):235-8.

Bibtex

@article{129bd783b6c84dfc956ead1d4ec28f62,
title = "Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma",
abstract = "BACKGROUND/AIM: Cyclin D1 gene (CCND1) has a G to A polymorphism at the splice donor site of exon 4, position 870. The A allele codes for a truncated variant, cyclin D1b, which may have higher transforming activity. Data regarding the predictive and prognostic value of the CCND1 G870A polymorphism in tumors are controversial. We aimed to examine this polymorphism in patients with oral carcinoma.MATERIALS AND METHODS: Genotyping of CCND1 G870A was determined by means of direct sequencing in 83 patients with oral carcinomas and in 102 healthy controls. Association with clinical outcomes was evaluated statistically.RESULTS: We failed to find any significant association of CCND1 G870A with risk of oral carcinomas in this German population, with clinical and pathological features of the tumours or with overall survival of the patients.CONCLUSION: Our results suggest that CCND1 G870A has no, or only very limited, predictive and prognostic value for oral carcinoma.",
keywords = "Carcinoma, Squamous Cell, Case-Control Studies, Cyclin D1, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Male, Middle Aged, Mouth Neoplasms, Neoplasm Recurrence, Local, Neoplasm Staging, Polymorphism, Single Nucleotide, Prognosis, Survival Rate",
author = "Artun Atac and Bj{\"o}rn Riecke and Assaf, {Alexandre T} and Alexander Gr{\"o}be and Friedrich, {Reinhard E} and Max Heiland and Izbicki, {Jakob R} and Lan Kluwe and Marco Blessmann",
year = "2014",
month = jan,
day = "1",
language = "English",
volume = "34",
pages = "235--8",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

RIS

TY - JOUR

T1 - Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma

AU - Atac, Artun

AU - Riecke, Björn

AU - Assaf, Alexandre T

AU - Gröbe, Alexander

AU - Friedrich, Reinhard E

AU - Heiland, Max

AU - Izbicki, Jakob R

AU - Kluwe, Lan

AU - Blessmann, Marco

PY - 2014/1/1

Y1 - 2014/1/1

N2 - BACKGROUND/AIM: Cyclin D1 gene (CCND1) has a G to A polymorphism at the splice donor site of exon 4, position 870. The A allele codes for a truncated variant, cyclin D1b, which may have higher transforming activity. Data regarding the predictive and prognostic value of the CCND1 G870A polymorphism in tumors are controversial. We aimed to examine this polymorphism in patients with oral carcinoma.MATERIALS AND METHODS: Genotyping of CCND1 G870A was determined by means of direct sequencing in 83 patients with oral carcinomas and in 102 healthy controls. Association with clinical outcomes was evaluated statistically.RESULTS: We failed to find any significant association of CCND1 G870A with risk of oral carcinomas in this German population, with clinical and pathological features of the tumours or with overall survival of the patients.CONCLUSION: Our results suggest that CCND1 G870A has no, or only very limited, predictive and prognostic value for oral carcinoma.

AB - BACKGROUND/AIM: Cyclin D1 gene (CCND1) has a G to A polymorphism at the splice donor site of exon 4, position 870. The A allele codes for a truncated variant, cyclin D1b, which may have higher transforming activity. Data regarding the predictive and prognostic value of the CCND1 G870A polymorphism in tumors are controversial. We aimed to examine this polymorphism in patients with oral carcinoma.MATERIALS AND METHODS: Genotyping of CCND1 G870A was determined by means of direct sequencing in 83 patients with oral carcinomas and in 102 healthy controls. Association with clinical outcomes was evaluated statistically.RESULTS: We failed to find any significant association of CCND1 G870A with risk of oral carcinomas in this German population, with clinical and pathological features of the tumours or with overall survival of the patients.CONCLUSION: Our results suggest that CCND1 G870A has no, or only very limited, predictive and prognostic value for oral carcinoma.

KW - Carcinoma, Squamous Cell

KW - Case-Control Studies

KW - Cyclin D1

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Lymphatic Metastasis

KW - Male

KW - Middle Aged

KW - Mouth Neoplasms

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Polymorphism, Single Nucleotide

KW - Prognosis

KW - Survival Rate

M3 - SCORING: Journal article

C2 - 24403468

VL - 34

SP - 235

EP - 238

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 1

ER -